NewLink ax­es 100 staffers, shrinks pipeline in wake of a PhI­II de­ba­cle

A lit­tle more than two months af­ter NewLink Ge­net­ics $NLNK was slammed by the Phase III fail­ure of its pan­cre­at­ic can­cer vac­cine al­gen­pan­tu­cel-L, the Ames, Iowa-based com­pa­ny has slashed 100 staffers and cut some of its clin­i­cal work in a painful re­struc­tur­ing.

The cuts, an­nounced ahead of the mar­ket open­ing Fri­day, will see off any Hy­per­A­cute Cel­lu­lar Im­munother­a­py clin­i­cal tri­als that don’t in­clude a check­point drug. The biotech is al­so shrink­ing its man­u­fac­tur­ing op­er­a­tions as well as its fa­cil­i­ties, emp­ty­ing out of about half of its head­quar­ters.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.